All Publications

Pages

1. • Journal article

   • 

   Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.

   Mansoor, Wasat Arkenau, Hendrik-Tobias Alsina, Maria Shitara, Kohei Thuss-Patience, Peter Cuffe, Sinead Dvorkin, Mikhail Park, David Ando, Takayuki Van den Eynde, Marc[UCL] Beretta, Giordano D Zaniboni, Alberto Doi, Toshihiko Tabernero, Josep Ilson, David H Makris, Lukas Benhadji, Karim A Van Cutsem, Eric (2021) Gastric cancer — Vol. 24, no. 4, p. 970-977 (2021)
2. • Speech

   • 

   FDG PET predicts prognosis of patients with resectable metastatic colorectal cancer (CRC) treated with preoperative chemotherapy

   Flamen, Patrick Huberty, V Garcia, Camilo Vanderlinden, Bruno Muylle, K Legendre, H Paesmans, Marianne Van den Eynde, Marc[UCL] (2007) 2007 ASCO Annual Meeting — (United States) Chicago, IL
3. • Speech

   • 

   Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: A randomized double-blinded placebo-controlled phase II trial.

   Demols, Anne Borbath, Ivan[UCL] Van den Eynde, Marc[UCL] Houbiers, Ghislain Peeters, Marc Maréchal, Raphael Delaunoit, Thierry Goeminne, Jean Charles. Laurent, Stéphanie Holbrechts, Stephane Paesmans, Marianne Van Laethem, Jean L. (2019) ASCO-GI : American society of clinical oncology - Gastrointestinal Cancers Symposium — (United States) San Francisco, CA
4. • Speech

   • 

   Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.

   Galon, Jerome Hermitte, Fabienne Mlecnik, Bernhard Marliot, Florence Bifulco, Carlo Bruno Lugli, Alessandro Nagtegaal, Iris D. Hartmann, Arndt Van den Eynde, Marc[UCL] Roehrl, Michael H. A. Ohashi, Pamela S Zavadova, Eva Torigoe, Toshihiko Patel, Prabhudas S. Wang, Yili Kawakami, Yutaka Marincola, Francesco Ascierto, Paolo Antonio Fox, Bernard A. Pages, Franck (2019) ASCO-GI : American society of clinical oncology - Gastrointestinal Cancers Symposium — (United States) San Francisco, CA
5. • Journal article

   • 

   Rationale and Design of the COPERNIC Trial: A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients.

   Assaf, Irene Bregni, Giacomo Anthoine, Geraldine Aparicio, Thomas Artru, Pascal Abdelghani, Meher Ben Buyse, Marc Chibaudel, Benoist Coart, Elisabeth Diaz, Marie Evrard, Camille Geboes, Karen Ghiringhelli, François Puleo, Francesco Raimbourg, Judith Vandamme, Timon Van den Eynde, Marc[UCL] Hendlisz, Alain Sclafani, Francesco (2025) Clinical colorectal cancer — Vol. 24, no.1, p. 101-105 (2025)
6. • Speech

   • 

   120P Avelumab (AVE), cetuximab (CET) and irinotecan (IRI) for treatment refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Characterization of the circulating immune response in the AVETUXIRI phase II trial

   Benidovskaya, Elena[UCL] Huyghe, Nicolas[UCL] Carrasco, Javier De Cuyper, Astrid[UCL] Sinapi, Isabelle Verstraelen, Eléonore[UCL] Goffette, Pierre[UCL] Ghaye, Benoît[UCL] Papier, M. Van Maanen, Aline[UCL] Castella, Marie-Laure[UCL] Galon, Jérôme Van den Eynde, Marc[UCL] (2024) the ESMO Gastrointestinal Cancers Congress 2024 — (Germany) Munich
7. • Speech

   • 

   Selective internal radiation therapy for neuroendocrine liver metastases: efficacy, safety and prognostic factors. A retrospective single institution study

   Briol, Damien[UCL] Ceratti, Antonino Annet, Laurence[UCL] Dragean, Cristina[UCL] Danse, Etienne[UCL] Trefois, Pierre Lhommel, Renaud[UCL] Goffette, Pierre[UCL] Van den Eynde, Marc[UCL] De Cuyper, Astrid[UCL] Borbath, Ivan[UCL] (2024) 36th Belgian Week of Gastroenterology — (Belgium) Antwerpen
8. • Speech

   • 

   International real-world study of total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC)

   Audisio, Alexandre Leuven Rectal Cancer Group Vanden Bulcke, Alexander Van den Eynde, Marc[UCL] Dermine, Alexandre Puleo, Francesco[UCL] Diaz, Marie Gilliaux, Quentin[UCL] Deleporte, Amélie Geboes, Karen Martinive, Philippe Vandamme, Timon Hendlisz, Alain van Laethem, Johan Sclafani, Francesco (2024) 36th Belgian Week of Gastroenterology — (Belgium) Antwerpen
9. • Journal article

   • 

   Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.

   Raghav, Kanwal Siena, Salvatore Takashima, Atsuo Kato, Takeshi Van den Eynde, Marc[UCL] Pietrantonio, Filippo Komatsu, Yoshito Kawakami, Hisato Peeters, Marc Andre, Thierry Lonardi, Sara Yamaguchi, Kensei Tie, Jeanne Castro, Cristina Gravalos Hsu, Hung-Chih Strickler, John H Kim, Tae-You Cha, Yongjun Barrios, Daniel Yan, Qi Kamio, Takahiro Kobayashi, Kojiro Boran, Aislyn Koga, Makito Allard, John D Yoshino, Takayuki (2024) The Lancet. Oncology — Vol. 25, no.9, p. 1147-1162 (2024)
10. • Speech

    • 

    600TiP A randomized blinded phase II study of ompenaclid (RGX-202-01) vs placebo in combination with FOLFIRI plus bevacizumab (BEV) in patients (pts) with previously treated RAS mutated (RASmt) advanced/metastatic colorectal cancer (mCRC)

    Elez Fernandez, M.E. Rosello Keranen, S. Paez, D. Jiménez Castro, J. Rivera Herrero, F. Ruiz-Casado, A. Riesco Martinez, M.C. Montagut Viladot, C. Coupez, D. Ducreux, M.P. Loly, C. Martin-Babau, J. Prenen, H. Van den Eynde, Marc[UCL] Borg, C. Cuyle, P-J. de Haar-Holleman, A. Raimbourg, J. Bechar, N. Tabernero, J. (2024) the ESMO Gastrointestinal Cancers Congress 2024 — (Germany) Munich
11. • Journal article

    • 

    STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer.

    Saeed, Anwaar Tabernero, Josep Parikh, Aparna Van den Eynde, Marc[UCL] Karthaus, Meinolf Gerlinger, Marco Wang, Zhong Wang, Guan Smith, Robina Hecht, J Randolph (2024) Future oncology — Vol. 20, no.24, p. 1733-1743 (2024)
12. • Speech

    • 

    LBA2 Interim efficacy analysis of REGINA, a phase II trial of neoadjuvant regorafenib (Rego), nivolumab (Nivo), and short-course radiotherapy (SCRT) in stage II-III rectal cancer (RC)

    Sclafani, F. Bregni, G. Assaf, I. Puleo, F. Vergauwe, P. Prenen, H. Diaz, M. Gokburun, Y. Sanchez, A. Veron Anthoine, G. Moretti, L. Gomez Galdon, M. Liberale, G. Martinive, P. Geboes, K. Carrasco, J. Van den Eynde, Marc[UCL] van Laethem, J-L. Buyse, M.E. Hendlisz, A. (2024) the ESMO Gastrointestinal Cancers Congress 2024 — (Germany) Munich
13. • Speech

    • 

    159TiP COPERNIC: A study of on-treatment circulating tumour (ct)DNA changes in chemo-refractory colorectal cancer (CRC) patients

    Assaf, Irene Bregni, Giacomo Anthoine, Géraldine Aparicio, Thomas Artru, Pascal Ben Abdelghani, Meher Chibaudel, Benoist Coart, Elisabeth Diaz, Marie Evrard, Camille Geboes, Karen Ghiringhelli, François Puleo, Francesco[UCL] Raimbourg, Judith Vandamme, Timon Van den Eynde, Marc[UCL] Hendlisz, Alain Sclafani, Francesco (2024) the ESMO Gastrointestinal Cancers Congress 2024 — (Germany) Munich
14. • Journal article

    • 

    Selective internal radiation therapy for neuroendocrine liver metastases: efficacy, safety and prognostic factors. A retrospective single institution study.

    Briol, Damien[UCL] Ceratti, Antonio[UCL] Lhommel, Renaud[UCL] Annet, Laurence[UCL] Dragean, Cristina[UCL] Danse, Etienne[UCL] Trefois, Pierre[UCL] Van den Eynde, Marc[UCL] De Cuyper, Astrid[UCL] Goffette, Pierre[UCL] Borbath, Ivan[UCL] (2025) Acta gastro-enterologica Belgica — Vol. 88, no.1, p. 3-11 (2025)
15. • Journal article

    • 

    Bacteria in metastatic sites: Unveiling hidden players in cancer progression.

    Stevens, Philippe Benidovskaya, Elena Llorens-Rico, Veronica Raes, Jeroen Van den Eynde, Marc[UCL] (2024) Cancer cell — Vol. 42, no.7, p. 1142-1146 (2024)

Pages